SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ:CNTA) and certain of its officers and directors. The class action, filed in the United States District Court for the Central District of California, and docketed under 22-cv-07030, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Centessa American Depositary Shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about May 28, 2021 (the "IPO" or "Offering"); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act").